<div class="table-responsive">
    <table class="table table-striped table-hover">
        <thead>
            <tr>
                
                <th scope="col">
                    <a href="?cresstrial=11471&amp;modal=1&amp;valnames=arms&amp;order=created_at">Created at</a>
                </th>
                <th scope="col">Source</th>
                
                <th scope="col">Raw Value</th>
                <th scope="col">Validated value</th>
            </tr>
        </thead>
        <tbody>
            
            <tr class="histvalue-row" histvalueid="418491" class="table-">
                
                <td>July 7, 2022, 1:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;D20.215.894.815.500;This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2556, &quot;treatment_name&quot;: &quot;Mmr vaccine&quot;, &quot;treatment_type&quot;: &quot;Non covid vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Non covid vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2187, &quot;treatment_name&quot;: &quot;Placebo&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;Placebo&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="417137" class="table-">
                
                <td>June 30, 2022, 4:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 774, &quot;treatment_name&quot;: &quot;Measles mumps rubella vaccine&quot;, &quot;treatment_type&quot;: &quot;Non covid vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Non covid vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2187, &quot;treatment_name&quot;: &quot;Placebo&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;Placebo&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="414287" class="table-">
                
                <td>June 17, 2022, 12:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;D20.215.894.815.500;This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 774, &quot;treatment_name&quot;: &quot;Measles mumps rubella vaccine&quot;, &quot;treatment_type&quot;: &quot;Non covid vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Non covid vaccine&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: 2187, &quot;treatment_name&quot;: &quot;Placebo&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;Placebo&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="295615" class="table-">
                
                <td>March 11, 2022, 3:30 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

        <p class="arms validated">
            [{&quot;arm_notes&quot;: &quot;2&quot;, &quot;treatment_id&quot;: 774, &quot;treatment_name&quot;: &quot;Measles mumps rubella vaccine&quot;, &quot;treatment_type&quot;: &quot;Non covid vaccine&quot;, &quot;pharmacological_treatment&quot;: &quot;Non covid vaccine&quot;}, {&quot;arm_notes&quot;: &quot;2&quot;, &quot;treatment_id&quot;: 2187, &quot;treatment_name&quot;: &quot;Placebo&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;Placebo&quot;}]
        </p>
        
    
                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="294837" class="table-">
                
                <td>Feb. 25, 2022, noon</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;D20.215.894.815.500;This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
            <tr class="histvalue-row" histvalueid="287831" class="table-">
                
                <td>Dec. 10, 2021, 2 p.m.</td>
                <td>oms</td>
                
                <td class="histvalue-container">
                    

        <p class="arms">
            [{&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).&quot;, &quot;treatment_type&quot;: &quot;TODO&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}, {&quot;arm_notes&quot;: &quot;&quot;, &quot;treatment_id&quot;: null, &quot;treatment_name&quot;: &quot;Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500&quot;, &quot;treatment_type&quot;: &quot;Placebo&quot;, &quot;pharmacological_treatment&quot;: &quot;TODO&quot;}]
        </p>
    

                </td>
                <td class="histvalue-container">
                    

                </td>
            </tr>
            
        </tbody>
    </table>
</div>
Created at	Source	Raw Value	Validated value
July 7, 2022, 1:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "D20.215.894.815.500;This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 2556, "treatment_name": "Mmr vaccine", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
June 30, 2022, 4:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 774, "treatment_name": "Measles mumps rubella vaccine", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
June 17, 2022, 12:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "D20.215.894.815.500;This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "", "treatment_id": 774, "treatment_name": "Measles mumps rubella vaccine", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
March 11, 2022, 3:30 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]	[{"arm_notes": "2", "treatment_id": 774, "treatment_name": "Measles mumps rubella vaccine", "treatment_type": "Non covid vaccine", "pharmacological_treatment": "Non covid vaccine"}, {"arm_notes": "2", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]
Feb. 25, 2022, noon	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "D20.215.894.815.500;This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]
Dec. 10, 2021, 2 p.m.	oms	[{"arm_notes": "", "treatment_id": null, "treatment_name": "This is a clinical trial for the evaluation of efficacy; Phase IV; randomized; double blind; placebo controlled to evaluate the efficacy of the MMR vaccine (MMR - measles; mumps and rubella) in prevention or decrease in the severity of COVID-19. 1000 volunteers from the region of Florian\u00f3polis; Brazil. The Research Coordinating Center for the Study will be the HPV Project Clinical Research Center HU / UFSC; composed of professors from this institution. Participants selected for the study health workers (doctors; nurses; nursing technicians) who are working on the front lines in the fight against COVID-19. They will be divided into 2 Groups: Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3). Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 1 (Drugs in study - MMR vaccine): 500 volunteers (men and women) aged 18 to 60 will receive 0.5 mL SC; in 2 doses with an interval of 8 weeks (Visit 1 and 3).", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}, {"arm_notes": "", "treatment_id": null, "treatment_name": "Group 2 (Placebo): 500 volunteers (men and women) from 18 to 60 years old will receive 0.5 mL SC saline solution (SF 0.9%); in 2 doses with an interval of 8 weeks (Visits 1 and 3). The objective of two doses; in this interval of 8 weeks is precisely to perform the \u201cTraining of the Innate Immune Response\u201d; offering a longer protection time; than the induced by just one dose. The expected protection is at least 6 months;D20.215.894.815.500", "treatment_type": "Placebo", "pharmacological_treatment": "TODO"}]